KDNY — Chinook Therapeutics Share Price
0.000.00%
Last trade - 00:00- $2.90bn
- $2.60bn
- $6.13m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.35 | ||
| Price to Tang. Book | 7.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 498.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -43.76% | ||
| Return on Equity | -51.56% | ||
| Operating Margin | -4101.29% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15.09 | 17.26 | 0.83 | 51.63 | 6.13 | 2.84 | 13.02 | -18.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.
Directors
- Eric Dobmeier CHM (52)
- Eric Bjerkholt CFO (61)
- Tom Frohlich COO (45)
- Andrew King CSO (41)
- Alan Glicklich OTH (59)
- Jerel Davis LED (44)
- Srinivas Akkaraju IND (53)
- William Greenman IND (54)
- Michelle Griffin IND (55)
- Ross Haghighat IND (57)
- Dolca Thomas IND (50)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- May 5th, 2011
- Public Since
- April 15th, 2015
- No. of Shareholders
- 89
- No. of Employees
- 214
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 67,049,489
- Address
- 400 Fairview Avenue North, Suite 900, SEATTLE, 98109
- Web
- https://www.chinooktx.com/
- Phone
- +1 2064857051
- Contact
- Noopur Liffick
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for KDNY
Q2 2023 Chinook Therapeutics Inc Earnings Release
Q3 2023 Chinook Therapeutics Inc Earnings Release
Similar to KDNY
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Chinook Therapeutics share price?
As of Today at 07:05 UTC, shares in Chinook Therapeutics are trading at $39.08. This share price information is delayed by 15 minutes.
How has the Chinook Therapeutics share price performed this year?
Shares in Chinook Therapeutics last closed at $39.08 and the price had moved by +114.25% over the past 365 days. In terms of relative price strength the Chinook Therapeutics share price has outperformed the S&P500 Index by +83.93% over the past year.
What are the analyst and broker recommendations for Chinook Therapeutics?
The overall consensus recommendation for Chinook Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Chinook Therapeutics dividend yield?
Chinook Therapeutics does not currently pay a dividend.
Does Chinook Therapeutics pay a dividend?
Chinook Therapeutics does not currently pay a dividend.
When does Chinook Therapeutics next pay dividends?
Chinook Therapeutics does not currently pay a dividend.
How do I buy Chinook Therapeutics shares?
To buy shares in Chinook Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Chinook Therapeutics?
As of the previous close price of $39.08, shares in Chinook Therapeutics had a market capitalisation of $2.62bn.
Where are Chinook Therapeutics shares listed?
Here are the trading details for Chinook Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: KDNY
What kind of share is Chinook Therapeutics?
Based on an overall assessment of its quality, value and momentum Chinook Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Chinook Therapeutics share price forecast for 2023?
The analyst consensus target price for shares in Chinook Therapeutics is $39.29. That is 0.54% above the last closing price of $39.08.
Analysts covering Chinook Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.21 for the next financial year.
What is the trend in the Chinook Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chinook Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +40.66%.
As of the last closing price of $39.08, shares in Chinook Therapeutics were trading +55.34% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Chinook Therapeutics PE Ratio?
The Chinook Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $39.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Chinook Therapeutics?
Chinook Therapeutics' management team is headed by:
- Eric Dobmeier - CHM
- Eric Bjerkholt - CFO
- Tom Frohlich - COO
- Andrew King - CSO
- Alan Glicklich - OTH
- Jerel Davis - LED
- Srinivas Akkaraju - IND
- William Greenman - IND
- Michelle Griffin - IND
- Ross Haghighat - IND
- Dolca Thomas - IND